Brought to you by 
Applied Molecular develops antibacterial with Biosynexus
13 Dec 2001
Executive Summary
Applied Molecular Evolution (gene optimization) has agreed to develop an optimized prophylactic agent for Biosynexus (drugs for hospital acquired infections) against staphylococcus infection in neonatal and pediatric patients.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Applied Molecular develops antibacterial with Biosynexus
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice